Breast Cancer Study of Preoperative Pembrolizumab + Radiation
Status:
Recruiting
Trial end date:
2022-02-21
Target enrollment:
Participant gender:
Summary
This study is being done to assess the feasibility of pembrolizumab (study drug) combined
with standard radiation to the tumor (tumor boost) before patients undergo standard treatment
that can consist of one or more of the following: breast-conserving surgery, radiation to the
entire breast/chest wall after surgery, and chemotherapy.
Study participants will receive two doses of the study drug intravenously (through the vein)
before their planned breast surgery or chemotherapy. The study drug will be administered
three weeks apart. At the time of the second dose, radiation to the tumor in the affected
breast will be given. This type of radiation treatment is called a "tumor boost", which is a
standard part of radiation therapy for breast cancer that may occur either before or after
planned breast-conserving surgery. Patients will receive breast surgery or begin chemotherapy
approximately six weeks after your first dose of the study drug.